Elixir raises $46M for fountain of youth
Elixir Pharmaceuticals, of Cambridge, Mass., said it has raised $46 million in a third round of funding. The financing includes $31 million in equity funding and $15 million in venture debt placement from Hercules.
The company is developing treatments for a number of diseases, mostly age-related. Here is a brief description of its technology.
The funding came from MPM Capital, Oxford BioScience Partners, ARCH Venture Partners, CDIB Ventures, JAFCO and YFY Biotech Management Company, among others.
Next Story: iSkoot, mobile Interent phone company, raises $6.2M from Khosla Ventures
Previous Story: Impedance Cardiology raises $5 million
Tags: co:Elixir
VentureBeat Writers
- Matt Marshall, Editor-in-Chief
- Dean Takahashi, Lead Writer, GamesBeat
- Anthony Ha, Assistant Editor, VentureBeat
- Camille Ricketts, Lead Writer, GreenBeat
- Paul Boutin, Writer, VentureBeat
- Kim-Mai Cutler, Writer, VentureBeat
- Matthaus Krzykowski, Mobile Consultant & Coordinator
VentureBeat Start-Up Index
An index of the hottest startups, measured by trends in their traffic, news coverage, buzz and funding.